Clene (NASDAQ: CLNN) to Meet with FDA to Discuss CNM-Au8 for ALS Treatment
Clene Inc., a late clinical-stage biopharmaceutical company, is set to meet with the FDA to discuss the development of its proprietary CNM-Au8 for the treatment of ALS. The meeting, scheduled before the end of November 2024, will include key FDA representatives and opinion leaders in the ALS space.
This news matters as it highlights Clene's efforts to develop a potential treatment for ALS, a devastating neurodegenerative disease. The meeting with the FDA signifies a crucial step in the development process, and if successful, CNM-Au8 could offer hope to ALS patients and their families.
